https://scholars.lib.ntu.edu.tw/handle/123456789/633119
標題: | Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use | 作者: | Yang, Cheng-Kuang Cha, Tai-Lung Chang, Yen-Hwa Huang, Shu-Pin Lin, Jen-Tai Wang, Shian-Shiang CHAO-YUAN HUANG Pang, See-Tong |
關鍵字: | Apalutamide; Castration-resistant prostate cancer; Darolutamide; Enzalutamide; Second-generation androgen receptor inhibitor | 公開日期: | 四月-2023 | 卷: | 122 | 期: | 4 | 來源出版物: | Journal of the Formosan Medical Association = Taiwan yi zhi | 摘要: | Darolutamide, a second-generation androgen receptor inhibitor (SGARI), has been shown to increase metastasis-free survival and overall survival among men with non-metastatic castration-resistant prostate cancer (nmCRPC). Its unique chemical structure potentially provides efficacy and safety advantages over the SGARIs apalutamide and enzalutamide, which are also indicated for nmCRPC. Despite a lack of direct comparisons, the SGARIs appear to have similar efficacy, safety, and quality of life (QoL) results. Indirect evidence suggests that darolutamide is preferred for its good adverse event profile, an attribute valued by physicians, patients, and their caregivers for maintaining QoL. Darolutamide and others in its class are costly; access may be a challenge for many patients and may lead to modifications to guideline-recommended regimens. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633119 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2022.12.008 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。